EXEnatide in patients undergoing Coronary artery bypass grafting for improved glUcose conTrol and hemodynamIc ValuEs - EXECUTIVE

General University Hospital in Prague0 个研究点开始时间: 2011年1月26日最近更新: 2016年11月14日

适应症

试验速览

暂无简介。

•- elective coronary artery bypass grafting operation (CABG) and/or valvuloplasty
•- LV systolic dysfunction (EF LV = 50%)
•- Age 18 - 85 years
•- Signed informed consent
•- Females with childbearing potential have to use appropriate contraceptive measures during the whole study period and 6 months after terminating exenatide infusion (hormonal contraception or double-barrier contraception for both partners)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 18

•- allergy to exenatide
•- allergy to insulin
•- mental incapacity or language barrier
•- use of incretin-based therapies <3 months before inclusion in the study
•- established autonomic neuropathy
•- history of acute pancreatitis or severe disease of digestive tract
•- renal failure (preoperative creatinine = 180 umol/l)
•- liver failure (coagulation times more than 1.5 times higher without use of anticoagulants)
•- cardiac surgical procedure on valve, thoracic aorta or MAZE procedure
•- diabetic ketoacidosis
•- pregnancy and lactation

发起方

General University Hospital in Prague